Form 4: Tarsus Pharmaceuticals Executive Exercises Stock Options and Acquires Shares

Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, reports the vesting and settlement of restricted stock units and acquisition of shares through the employee stock purchase plan.

Summary

• On March 15, 2025, Aziz Mottiwala, Chief Commercial Officer of Tarsus Pharmaceuticals, executed transactions involving the company's stock.
• Mottiwala acquired 20,957 shares of common stock.
• These shares were obtained through the settlement of vested Restricted Stock Units (RSUs).
• He also acquired shares under the Issuer's Employee Stock Purchase Plan on June 30, 2024 and December 31, 2024.
• Mottiwala now beneficially owns 75,622 shares of Tarsus Pharmaceuticals.
• The transactions involved the vesting of 4,790 RSUs granted on March 9, 2022, 8,148 RSUs granted on March 8, 2023, and 8,019 RSUs granted on March 7, 2024.
• These RSUs vest in 25% increments annually.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating standard compensation practices. The executive's increased stake could be seen as a positive sign, but it's not a major event.

Positives

• The vesting of RSUs and participation in the employee stock purchase plan indicate Mottiwala's continued investment in the company's future.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows confidence from a key executive.

Key Dates